Nanoligent — Seed · €2.8M

Nanoligent, a spin-off of the Universitat Autònoma de Barcelona and the Sant Pau research institute, closed its first round of €1 million co-led by Italian Angels for Growth and AVANTECA Partners, with the Italian platform Doorway also investing. The money funds preclinical development of its nanoconjugate drugs that selectively kill metastatic cells overexpressing the CXCR4 receptor.

LeadItalian Angels for Growth, AVANTECA Partners RoundSeed Announced3 Feb 2022 CityBarcelona SectorHealthtech & Bio · Biotech Source W

Extended 27 Sep 2022: +€1.8M from i&i Biotech Fund

Something wrong? Suggest a correction →